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Analytical antiretroviral treatment interruption (ATI) is an important feature of HIV research, seeking to achieve 
sustained viral suppression in the absence of antiretroviral therapy (ART) when the goal is to measure effects of 
novel therapeutic interventions on time to viral load rebound or altered viral setpoint. Trials with ATIs also intend 
to determine host, virological, and immunological markers that are predictive of sustained viral control off ART. 
Although ATI is increasingly incorporated into proof-of-concept trials, no consensus has been reached on strategies 
to maximise its utility and minimise its risks. In addition, differences in ATI trial designs hinder the ability to 
compare efficacy and safety of interventions across trials. Therefore, we held a meeting of stakeholders from many 
interest groups, including scientists, clinicians, ethicists, social scientists, regulators, people living with HIV, and 
advocacy groups, to discuss the main challenges concerning ATI studies and to formulate recommendations with 
an emphasis on strategies for risk mitigation and monitoring, ART resumption criteria, and ethical considerations. 
In this Review, we present the major points of discussion and consensus views achieved with the goal of informing 
the conduct of ATIs to maximise the knowledge gained and minimise the risk to participants in clinical HIV 
research.
Background
Despite the success of modern antiretroviral therapy 
(ART) in limiting HIV replication, HIV infection 
remains a chronic disease that long-term ART alone will 
probably never eliminate. Thus, efforts to eradicate HIV 
infection, or at least induce a state of ART-free viral 
suppression, are being vigorously pursued. To ultimately 
validate promising strategies, analytical antiretroviral 
therapy interruptions (ATI) appear to be necessary until 
a promising biomarker that robustly predicts post-
treatment viral control emerges; therefore, so far, ATIs 
are irreplaceable. Despite the important role of ATIs in 
HIV research, clinical trial designs that include ATIs 
have been quite heterogeneous, hindering the ability to 
compare efficacy an d sa fety of  in terventions an d AT Is 
across trials. Therefore, on July 9, 2018, we convened a 
forum at the Ragon Institute of MGH, MIT and Harvard 
in Cambridge, Massachusetts, USA, to assess the 
scientific v alue, r isks, b enefits, an d me thods of  AT Is, 
including the ethical and community perspectives of 
these approaches. Our goal was to formulate 
recommendations for the conduct of ATIs in a manner 
that maximises the knowledge gained and minimises 
the risk to trial participants. This Review summarises 
the major points of discussion (panel) and any consensus 
viewpoints that were achieved. It is expected that this 
meeting is the beginning of an ongoing discussion on 
how to conduct ATIs that will continue to evolve 




41 experts on HIV research (adult and paediatric 
clinicians; virologists and immunologists; bioethicists; 
patient advocates; statisticians; social scientists; and 
representatives of regulatory authorities and funding 
agencies [US Food and Drug Administration, US 
National Institutes of Health, and AmfAR]) and industry 
from Denmark, South Africa, Spain, Switzerland, 
Thailand, the UK and the USA, participated by invitation 
from the scientific committee (BJ, LD, JA, DHB, MLR, 
NLM, JWM, SGD, and BDW). Main challenges 
concerning ATI studies were identified before the 
meeting, including establishing strategies for risk 
mitigation, monitoring and ART resumption criteria, 
and evaluating ethical considerations. Four panels were 
established to prepare and present expert opinions on 
assigned topics and to formulate a set of questions for 
which opinion of the larger group was considered crucial. 
Panel presentations were followed by an open group 
discussion and concluded with an electronic, anonymous 
poll on selected questions. A manuscript detailing 
recommendations was prepared by the scientific 
committee and then circulated to the larger group for 
review and revision. The recommendations presented in 
this manuscript are largely based on expert opinions 
given the paucity of clinical evidence specific to ATIs and 
the limited availability of randomised controlled trials. 
The references used in this document were identified by 
literature search focusing on reported clinical studies, 
including observational, cohort, or interventional studies 
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in which ART was temporarily interrupted with 
predetermined restart criteria. We have adhered to the 
policies for protection of human subjects as prescribed 
in AR-70–25.
Results
Are ATIs appropriate and what are the risk–benefit 
justifications?
The group agreed that validated biomarkers predictive of 
virological control once ART is stopped are not yet 
available, which means ATIs are the only way to test the 
efficacy of new therapeutic interventions. Even if a 
promising biomarker emerges, validating its utility as a 
surrogate marker for an ATI read-out will prove 
challenging because an effective intervention that clearly 
affects time-to-rebound or post-treatment control does 
not yet exist. Although some progress in identifying 
candidate biomarkers that might prove to be predictive 
has been made,1–4 and prospective observational studies 
aimed at supporting biomarker discovery are ongoing 
(eg, NCT03117985, NCT03225118, NCT03001128), no 
robust markers or assays that could replace ATIs are yet 
available.
Although the meeting participants acknowledged that 
potential risks exist for study participants undergoing 
ATIs, evidence thus far has not indicated a sustained 
effect of short-term ATIs on the HIV reservoir. Findings 
from a study5 have shown that measurements of the 
reservoir at different timepoints following ART 
interruption, at least based on HIV DNA concentrations, 
indicate that it takes up to 60 weeks for the reservoir to 
significantly expand compared with pre-ATI levels (but 
this expansion might depend on the magnitude of viral 
replication during the ATI. In the same study, HIV DNA 
concentrations returned to pre-ATI values within 
6 months following ART reinitiation with the pre-ATI 
regimen. Another study6 showed that, following a long 
ATI of 48 weeks, total HIV-1 DNA concentrations 
returned to the pre-ATI amount after ART resumption, 
but that integrated HIV-1 DNA remained elevated at least 
for the duration of the study follow-up (104 weeks after 
resumption of ART). It has also been shown that over 
4–6 weeks of ATI, viral diversity does not increase.7–9 
Although the potential effect of an ATI on the size of the 
reservoir was discussed as a potential risk, no consensus 
was reached regarding the effects of ATIs that do not last 
longer than several months.
The majority of meeting participants agreed that ATI 
studies are justifiable if the risk is adequately understood 
by the participant, and if the study design will answer a 
scientific question that could not be solved otherwise or 
can be solved efficiently (appendix p 1). There was strong 
consensus, however, that ATIs are highly context 
dependent, and that one single guideline for all 
circumstances under which ATIs are appropriate is not 
feasible. The group agreed that the responsibility is on 
investigators to show, before the ATI study, that a strong 
Panel: Key recommendations
Inclusion criteria
• Stable CD4 counts ≥500 cells per µL*
• HIV RNA undetectable on stable ART†
• Otherwise healthy individuals without major comorbidities
Key exclusion criteria
• Active or chronic hepatitis B virus infection, with detectable hepatitis B surface 
antigen, hepatitis B virus DNA, or both
• Active hepatitis C virus infection, with detectable virus RNA
• Active Mycobacterium tuberculous infection‡
• History of systemic cancers, such as Kaposi’s sarcoma and lymphoma, or other 
virus-associated malignancies§
• History of HIV-associated dementia or progressive multifocal leukoencephalopathy
• Resistance to two or more classes of antiretroviral drugs¶
• History of cardiovascular event or at high risk of an event (eg, atherosclerotic 
cardiovascular disease score >15%)
• History of AIDS-defining illness according to Centers for Disease Control and 
Prevention criteria
• History of CD4 nadir <200 cells per µL during chronic stages of infection
• Women who are pregnant or breastfeeding
• Advanced non-alcoholic fatty liver and advanced nonalcoholic steatohepatitis, 
if evidence for substantial fibrosis (fibrosis score ≥F2) or evidence of cirrhosis
• HIV-related kidney disease or moderate-to-severe decrease in estimated glomerular 
filtration rate (<45–60 mL/min/1·73 m²)
• Children younger than 2 years of age when the ATI is planned
Monitoring
• HIV RNA monitoring weekly for 12 weeks, then every other week
• CD4 count monitoring every two weeks 
• Monitoring of clinical symptoms, in particular in people who started ART during the 
hyperacute HIV phase
• Monitoring of participants’ psychosocial experiences
ART restart criteria
• If requested by the participant or their HIV health-care provider
• If participant becomes pregnant
• If ART is deemed medically necessary for non-HIV related causes
• Symptomatic HIV disease||
• Confirmed absolute CD4 value <350 cells per µL or CD4% <15%**
• HIV RNA ≥1000 copies per mL for 4 weeks††
• Absolute HIV RNA >100 000 copies per mL††
Reducing risk of HIV transmission to sexual partners
• Offer pre-exposure prophylaxis and HIV testing referral information that trial 
participants can provide to their sexual partners
Additional or more stringent criteria might be required based on known toxicities of the study drug(s) or expected risks of the 
study intervention(s). Inclusion and exclusion criteria, monitoring, and antiretroviral therapy (ART) restart criteria might differ 
in children depending on age. ART=antiretroviral therapy. *Baseline CD4 counts of ≥350 cells per µL might be considered. 
†Based on FDA-approved HIV RNA quantification assay.‡ Latent tuberculosis infection discussed in the text. §Other 
malignancies discussed in the text. ¶Defined as single key mutations or an accumulation of minor mutations that result in 
resistance to entire respective drug classes. ||Symptoms include, but are not limited to, unintentional weight loss 
(>5–10% of the pre-ATI bodyweight), otherwise unexplained persistent fever (>100·4ºF/38ºC), persistent night sweats, 
persistent diarrhoea, oral candidiasis and generalised lymphadenopathy. **Largely dependent on the CD4 entry criteria; 
a sufficiently large delta between the entry value versus CD4 measurement for ART resumption should be ensured. 
††12–16 weeks of uncontrolled viraemia, with HIV RNA of more than 100 000 copies per mL; it might be acceptable in studies 
in which a stable viral set point is a primary endpoint.
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scientific rationale exists for why the intervention might 
conceivably affect time-to-rebound, postinterruption 
setpoint, or other meaningful biological or clinical 
endpoints. This rationale might include previous success 
in preclinical animal models (eg, rhesus macaques, 
humanised mice), success in other diseases (such as 
cancer), or previous evidence that the inter vention has a 
measurable effect on a relevant biomarker in humans, 
such as the size of reservoir or generation of potentially 
protective HIV-specific immune responses. In this 
context, it was suggested that investigators who want to 
develop a new therapeutic strategy should determine 
predefined go/no-go criteria (which define whether 
interventions should progress to the next stage of 
development) for incorporating ATIs in their 
development plans. More importantly, researchers 
should determine criteria for whether an intervention 
has achieved predefined goals ( eg, stipulating that a 
therapeutic vaccine induces immune responses above a 
prespecified threshold) before subjecting participants to 
an ATI. In general, the group agreed that ATIs should 
not be used in the absence of supporting data simply to 
generate hypotheses.
Which participants should be included in ATI studies?
It is important to balance feasibility and risk mitigation 
with the likelihood of successfully conducting a trial. If a 
study only allows individuals with very restricted CD4 
nadir and age limits, it might be difficult to enrol 
sufficient participants; might exclude a large proportion 
of the HIV infected population, thereby precluding their 
contribution to and participation in HIV research; and 
would limit generalisability of findings to the broader 
population of people with HIV. Although proof-of-
concept studies often target populations in which a study 
intervention might have the highest likelihood of a 
detectable effect, age limits and CD4 nadir ranges that 
are more reflective of the overall demographics of the 
HIV infected population (eg, age limits of 65 or 70 years) 
might be considered. Nonetheless, it should be noted 
that the US FDA considers people with ART-controlled 
HIV infection who are asymptomatic and have many 
available treatment options to be more similar to healthy 
volunteers than to patients with life-threatening 
conditions with limited to no treatment options (eg, 
refractory, advanced malignancies). In line with the 
obvious ethical considerations, investigators must 
carefully consider the potential ramifications of any 
interventions to trial participants, because the
acceptability of risk to healthy volunteers is low in clinical 
research.
The group agreed that no single population was best 
for all ATIs. There was consensus that ATI studies, which 
are largely experimental, should focus on otherwise 
healthy individuals with well controlled HIV who do not 
have substantial or serious comorbidities. Because 
experimental studies can involve relatively long ATIs, 
high viraemia, or both, investigators should seek 
participants who are expected to have a functional 
immune system, and who can probably tolerate a period 
of high viraemia or any viraemia occasioned by 
infrequent viral load monitoring. Therefore, an 
agreement that participants in ATI studies should have 
stable CD4 counts of equal or greater than 500 cells per 
µL was reached. However, support was also given for 
allowing CD4 counts of equal to or greater than 350 cells 
per µL (appendix 2). The decision regarding which CD4 
count threshold to allow for enrolment will depend on 
the presumed overall risk of the studied intervention. As 
clinical studies progress, the standards of what is 
acceptable might also change as risks become better 
defined. There was strong agreement that the influence 
of sex, gender, race, ethnicity, and geographic location on 
ATI outcomes also require further investigation. For 
example, women in the USA have been rarely recruited 
for these studies,10 although the AIDS Clinical Trial 
Group (ACTG) A5366 study (NCT03382834) successfully 
and quickly enrolled 30 postmenopausal women showing 
that recruit ment of women is feasible (Gandhi RT, 
unpublished). Results from a study11 published in 2018, 
suggested that post-treatment control was more common 
among African individuals compared with non-African 
individuals, suggesting that ethnicity might be associated 
with treatment outcomes; however, all participants in 
this study were women, preventing disaggregation by 
sex.11 Strategies aimed at improving sex and gender 
balance are, therefore, clearly needed.12,13
Paediatric considerations are also important. The 
inclusion of paediatric participants in ATI studies is a 
complex issue. Paediatric HIV disease spans an age 
range from neonates to 24 years, and thus encompasses 
many distinct groups and development stages. Key safety 
concerns for younger groups include neurodevelopmental 
risks, uncertainty whether the immune system is 
sufficiently robust, and potential risks that are not yet 
known or understood. Timely ART in children can have 
very positive results (eg, improved responses to 
vaccination, or the absence of neurological and metabolic 
comorbidities). However, in contrast to adults with HIV 
for whom one tablet a day is feasible, continuous 
adherence to ART from birth is difficult to achieve, with 
unplanned treatment interruptions being common, 
especially in low-income and middle-income settings 
where the paediatric epidemic is concentrated. 
Furthermore, the long-term side-effects of continuous 
ART from birth are unknown and should not be 
dismissed. Paediatric patients might arguably benefit the 
most from strategies that induce ART-free viral 
suppression and incorporating paediatric populations 
into research geared towards this goal is, therefore, 
crucially important. Furthermore, some concerns in 
adults, such as HIV transmission to a sexual partner, do 
not exist during early childhood. There was an overall 
agreement that because of the unique risks and 
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behaviours surrounding paediatric patients with HIV, 
dedicated age group-specific recommendations should 
be generated.
What should be considered strict exclusion criteria?
Several conditions and populations were considered to 
define strict exclusion criteria for ATIs: active co-
infection, cancer, neurological concerns, ART resistance, 
cardiovascular disease, history of AIDS defining illness 
and CD4 nadir, pregnancy, renal and liver disease, risk of 
HIV transmission to sexual partners of ATI study 
participants, and paediatric populations.
There was a strong consensus that patients with 
chronic hepatitis B virus infection, detectable hepatitis B 
surface antigen or hepatitis B virus DNA, active 
hepatitis C virus infection, or detectable hepatitis C virus 
RNA should be strictly excluded. The group reached a 
consensus that individuals who have been fully treated 
for and cured of hepatitis C or who have cleared the virus 
naturally, and have documented undetectable plasma 
hepatitis C virus RNA, do not need to be excluded. Other 
co-infections, for example Mycobacterium tuberculosis, 
need to be considered, specifically given the high 
prevalence of M tuberculosis infection among people with 
HIV in certain geographic locations.14 Although active 
M tuberculosis infection should be an exclusion criterion, 
the possibility of reactivating latent M tuberculosis 
infection should be discussed and preventive treatment 
might be considered.
HIV is associated with increased risk of many cancers. 
For certain cancers, any medical history should 
be generally considered strict exclusion criterion (eg, 
systemic cancers such as Kaposi’s sarcoma and lymphoma, 
or other virus-associated malignancies). However, patients 
in Berlin, Germany,15 and Boston, USA16 underwent ATI 
following treatment for haematological malignancies and 
the risk–benefit ratio for participants like these needs to 
be assessed on a case-by-case basis. An association 
between HIV infection, smoking, and an elevated risk of 
lung cancer has been suggested,17 and although smoking 
status (current or former) should not qualify for exclusion, 
individuals with previous history of lung cancer might be 
excluded. Patients should also be screened for cervical and 
anal cancer, and excluded if the result is positive. It is 
important to consider the specific type of malignancy 
relevant to each individual, because a history of certain in-
situ cancers or a history of cancers not known to be 
associated with HIV (eg, prostate cancer, breast cancer, or 
colon cancer) might not justify as an exclusion (appendix 
p 3). Certain limitations—eg, remission stage for more 
than 10 years—could be considered.
Overall, the potential for neurological and CNS 
problems during acute or sustained viraemia are real, but 
poorly defined, risks of ATIs. Previous experience with 
cerebrospinal fluid monitoring during prolonged ART 
interruption indicated rebound of HIV RNA accompanied 
by elevations in biomarkers of intrathecal inflammation 
and neuronal injury by approximately 20 days after 
ATI.18–20 However, the clinical consequences of these 
changes are unknown. Thus far, the risk for a neurological 
adverse event in the context of ATI appear low, although 
aseptic meningitis as a sign of acute retroviral syndrome 
has been reported.16,21 In general, patients with a history of 
HIV-associated dementia or progressive multifocal 
leukoencephalopathy should be excluded. HIV-associated 
dementia is associated with neuroinflammation, 
neuronal injury, and a high burden of HIV replication in 
the CNS that is typically genetically compartmentalised 
with respect to the blood, suggesting a CNS cellular 
source.22,23 These pathologies are improved by ART.24 
However, residual low-grade intrathecal immune 
activation and HIV RNA detection in the CNS despite 
suppression in the plasma suggest that the brain is a site 
of HIV persistence, which might be vulnerable to further 
injury or development of local ART resistance with CSF 
escape during recrudescence of viral replication and 
inflammation.25,26 Progressive multifocal leukoence phalo-
pathy is a frequently fatal disorder caused by CNS 
infection with the John Cunningham virus for which an 
effective antiviral therapy is not yet available.27 Immune 
competence is essential for John Cunningham virus 
control and irreversible brain injury persists in individuals 
who survive progressive multifocal leukoencephalopathy.
The potential emergence of new drug-resistance 
mutations is of concern. Drug resistance might occur 
during the interruption phase or when ART is resumed. 
Specifically, stopping ART regimens containing anti-
retrovirals with different serum half-lives, which results, 
for example, in delayed wash-out of non-nucleoside 
reverse-transcriptase inhibitors (NNRTIs) among other 
drugs, poses a risk for the development of drug resistance. 
The treatment of study participants on such regimens 
should be switched to short-acting antiretrovirals (eg, 
switching NNRTIs to integrase inhibitors) before an ATI. 
Although one study7 reported no evidence of new 
antiretroviral drug resistance mutations within intact 
sequences of HIV proviral DNA following reinitiation of 
ART, one patient in a different study16 developed the 
K103N mutation during ART reinitiation due to 
adherence issues caused by an acute retroviral syndrome. 
Based on these observations, the consensus was that 
studies should only enrol individuals who have multiple 
alternative ART options available in case their current 
treatment becomes less effective. Excluding individuals 
who have resistance to two or more classes of drugs 
(defined as single key mutations or an accumulation of 
minor mutations that result in resistance to entire 
respective drug classes) was also supported (appendix p 3).
The association between cardiovascular risk and ATI is 
debatable. Although some investigators strictly exclude 
individuals with any cardiovascular risk or history, others 
might allow certain cases, such as individuals who have a 
distant history of disease and who have been treated and 
stable for many years. The group reached a consensus 
that all potential study participants should be screened for 
signs and symptoms of cardiovascular disease before 
taking part in an ATI study. If findings on initial screening 
raised concern, additional testing for cardiovascular 
disease should be done before enrolment. Individuals 
with a known cardiovascular event or at high risk of an 
event (eg, Atherosclerotic Cardiovascular Disease Score 
>15%) should be excluded (appendix p 3).
Approximately two-thirds of meeting participants
concluded that anyone with a history of AIDS-defining
illness according to Centers for Diseases Control and
Prevention criteria should be excluded (appendix p 3). In
addition, the occurrence of AIDS-defining illnesses is, in
most cases, linked to a CD4 nadir, which by itself is a
criterion for determining eligibility. Therefore, the
general consensus was that individuals with a lifetime
CD4 nadir of less than 200 cells per µL should be
excluded, regardless of whether they are on stable
treatment with higher CD4 T-cell counts. Moreover, there
was some support within the group that a lifetime CD4
nadir of less than 350 cells per µL should be considered
to be an exclusion criterion while we are still in the early
stages of conducting ATI studies. Overall, there was also
consensus that investigators should carefully consider
the context of their study when choosing a CD4 nadir
cutoff. Individuals with acute infection can have a
substantially decreased CD4 count, even of less than
200 cells per µL. However, this decrease is transient and
might not reflect immune deficiency as observed in CD4
declines during chronic stages of infection. A hard cutoff 
that does not account for this transience might exclude a
substantial number of potential participants and, there-
fore, the group suggested to consider primarily CD4
nadir limits outside of the acute infection window.
Women who are pregnant or breastfeeding should be
strictly excluded, as suppression of viraemia is crucial to
prevent mother-to-child transmission. Careful moni-
toring for pregnancy should be a component of all ATI
protocols. Trial participants should also be counselled on
avoiding pregnancy during the trial. This counselling
includes contraception and, if necessary, referral to a
health-care provider for provision of contraceptives.
Because of the emphasis on recruiting more women into
such trials, efforts to avoid pregnancies should also be
fully incorporated into all protocols.
Patients with non-infectious liver disease (including
advanced non-alcoholic fatty liver and advanced non-
alcoholic steatohepatitis), should be excluded if evidence
of substantial fibrosis (fibrosis score ≥F2) or cirrhosis
determined by histology, imaging, or non-invasive
measurements, is found. Individuals with HIV-associated 
kidney disease should also be excluded. Furthermore, a
moderate-to-severe decrease in estimated glomerular
filtration rate (<45–60 mL/min/1·73 m²) should be an
exclusion criterion (appendix p 3).
Although HIV transmission is among the greatest
risks during an ATI, participants undergoing ATIs might
also face legal and even criminal charges should they 
transmit HIV while off ART.28 Thus, HIV transmission 
must be vigilantly prevented for the safety of both 
partners and participants. Therefore, a consensus was 
reached that, at a minimum, participants must be clearly 
and comprehensively counselled on transmission risks. 
The majority of the meeting participants thought that 
having HIV-negative sexual partners who are not 
accessing pre-exposure or post-exposure prophylaxis 
should not in itself be an exclusion criterion for a 
potential participant of an ATI study (appendix p 3). 
However, counselling should be offered, as well as 
education about pre-exposure or post-exposure 
prophylaxis and HIV testing referral that trial participants 
can provide to their sexual partners. There was some 
consideration that pre-exposure prophylaxis might be 
made available upon request by the study to the 
participant’s sexual partner(s). Despite this general 
intention, providing protection for the sexual partners of 
trial participants presents a great challenge due to the 
conflict between the ethical obligation of protecting a 
participant’s confidentiality and warning, or otherwise 
protecting, known and unknown sexual partners of a 
participant who is undergoing an ATI and who might 
have a viral rebound. As an additional complicating 
factor, it was noted that research funding generally does 
not extend to providing care to sexual partners of study 
participants (appendix p 4).
Regarding paediatric populations, there was a 
consensus that all children who are younger than 2 years 
of age should be excluded (appendix p 5) from ART 
interruption because of their developing immune 
systems and potential elevated neurodevelopmental risks 
associated with unsuppressed viraemia, coupled with the 
feasibility for frequent viral load monitoring off ART. The 
group was also concerned that younger children who are 
not chronic survivors might have exponential increases 
in viraemia and disease progression, compared with 
older children who have reached a partial controller state 
in the absence of ART. Similarly to adults, any children 
who have resistance to two or more classes of drugs 
should be strictly excluded.
What is considered adequate monitoring during the ATI 
phase?
The consensus was that, in most circumstances, once 
weekly monitoring is a reasonable frequency. Although 
more frequent testing might be desired from a clinical 
and scientific perspective, it is necessary to consider the 
very real burden this frequency presents to participants 
and monitoring frequency must be balanced against 
participant retention, especially in studies lasting 
6–12 months. It was agreed that the early weeks of ATI 
warrant the most thorough testing. Specifically, partici-
pants should be monitored weekly for 12 weeks, and 
testing frequency might be decreased to every other week 
thereafter, with the option of resuming weekly 
monitoring if necessary (eg, when rebound of viraemia 
occurs; appendix p 6). The rationale for frequent 
monitoring in the initial 12 weeks is based on the 
observation that the majority of individuals rebound 
during this time.29,30 Frequent early testing is thus crucial 
to detect rebound with precision. Nevertheless, it was 
noted that less frequent monitoring in later weeks could 
also result in undetected viraemia.
Viraemia, clinical symptoms, and CD4 counts need to 
be considered. There was consensus that viraemia is a 
crucial measurement as virological rebound might be the 
earliest evidence of disease activity and can precede other 
symptoms by days. Clinical symptoms should also be 
carefully monitored, and the risk of acute retroviral 
syndrome needs to be considered following viral 
rebound. Specific clinical signs and symptoms that raise 
concern for this condition include malaise, fever, 
headache, lymphadenopathy, rash, sore throat, myalgia 
or arthralgia, unintentional weight loss, night sweats, 
and diarrhoea.31,32 Although CD4 counts should be 
measured every 2 weeks and included in the ART restart 
criteria, they are less sensitive than measuring viraemia 
as CD4 decline often is slower.
Home testing is another important consideration. Viral 
load testing at home has several key advantages. It allows 
increased participant monitoring without the need of 
frequent clinic visits and is much more convenient for 
participants. Although such assays are not formally 
licensed, they are being explored for screening of viral 
rebound33 and to decide when to do formal viral load 
quantification in the clinic. However, home testing 
introduces an important caveat. The precision in 
estimating time to rebound depends on testing 
frequency; therefore, the precision of home testing 
depends heavily on the adherence of the participants to a 
testing schedule (either more or less frequent testing 
than scheduled would affect the study outcome). 
Furthermore, home testing does not allow the verification 
of the sample source by the clinical team because it does 
not occur during an observed blood draw at the study 
clinic and relies on the study participant’s veracity.
Monitoring considerations are also important for 
people who started ART during the so-called ‘hyperacute’ 
HIV phase. The consensus was that unique issues are 
associated with ATI participants who started ART very 
early, generally defined as preseroconversion (Fiebig 
stage 1–2 or hyperacute HIV infection). Specifically, these 
individuals have never seroconverted and potentially will 
not have appreciable anti-HIV immunity but might 
seroconvert after an ATI and, hence, be at higher risk for 
acute retroviral syndrome.34 Because becoming HIV 
antibody positive might pose legal risks, such as 
disqualification for enlisting into military service in some 
countries, might carry potential social harm (eg, stigma 
associated with HIV infection and HIV-related 
discrimination), and might have serious financial 
implications, participants should be informed of these 
possibilities during informed consent and carefully 
monitored for such issues, and appropriate support and 
counselling should be offered.
Monitoring of participants’ psychosocial experiences 
during ATIs is crucial. There was consensus that the 
psychosocial and lived experiences of study participants 
should be strategically assessed during analytical treat-
ment interruptions. The large majority of the meeting 
participants agreed with integrating sociobehavioural 
assessments and monitoring of study participants in HIV 
ART-free remission protocols using ATIs (appendix p 7).35 
This assessment would involve participants’ motivations, 
needs, concerns, and perceptions throughout the study. 
There was a consensus on the fact that researchers should 
also examine participants’ psychosocial tolerance for 
longer ATIs, particularly because the research field moves 
towards less restrictive ATIs and prolonged periods of 
viraemia. Cohort studies of people with acute HIV 
infection in Thailand have successfully integrated 
decision-making assessments in HIV remis sion protocols 
with ATIs.36 Similar research is ongoing in the USA as 
part of the ACTG and HIV ART-free remission-related 
research at the end of life.37 Overall, the consensus was 
that research protocols should include formal monitoring 
of both perceived health and non-health associated 
benefits, and also perceived risks, such as anxiety related 
to being off ART, stress related to becoming viraemic, and 
fear of transmitting HIV to sexual partners.
Regarding paediatric populations, the consensus was 
that they should be monitored differently (eg, adolescents 
who are sexually active vs younger paediatric patients). 
The challenges are different between paediatric and adult 
populations, including more demanding blood draws, 
reliance on parents for clinic visits, and disruption of 
school schedules. Although in an ideal scenario the 
duration of weekly monitoring would be at the least 
similar to the proposed adult schedule, or even extended 
beyond the 12 weeks, the specific issues with feasibility 
and participant burden in the paediatric populations 
might require every-other-week monitoring early in the 
ATI period.
The group agreed that drug concentrations should also 
be assessed in initial weeks and throughout the ATI 
phase to confirm that individuals have indeed stopped 
ART. Although this strategy would prevent the risk of 
misinterpretation of study outcomes, it would also add to 
participant safety as termination from the study would 
allow a participant to take ART openly rather than 
covertly. Further, even in the event that participants 
achieve post-treatment control, investigators should be 
mindful that it might not be clinically optimal, despite 
the scientific merit of the finding. ART might still be 
advisable for controllers to ensure their safety, and that of 
their partners because ART-free viral control might be 
associated with ongoing low viral replication and 
potentially increased systemic inflammation.38,39 There 
was consensus that ATI studies should be done in areas 
where an established infrastructure is available for 
contacting and monitoring patients during ATIs, and for 
resuming ART promptly.
When should ART be re-initiated?
The general consensus of the group was that ART should 
be restarted if requested by the participant or their HIV 
health-care provider, if a participant becomes pregnant, 
or if ART is deemed medically necessary for non-HIV 
related causes. For HIV-specific restart criteria, it was 
agreed that viraemia should be a major criterion; 
however, the choice of a virological endpoint should 
generally depend on the study objectives.
Time to rebound might be considered the safest 
endpoint in an ATI protocol. It involves frequent mon-
itoring of plasma HIV RNA with real-time measurements. 
Once HIV viral load rebound is confirmed and the 
endpoint is achieved, ART can be resumed. The time-to-
rebound can be used as a test of cure as shown in some 
studies.1,40,41 It might also prove to be a useful surrogate 
for the overall reservoir size, which is being investigated 
in an ongoing ACTG trial (A5345). In contrast, many 
immune-based therapeutics seek to achieve control of 
HIV after ART is interrupted and setpoint of rebound 
might be, therefore, the more appropriate measure. It 
has been observed in elite controllers, post-treatment 
controllers, and several successful cure and remission 
studies in non-human primates, that a period of high 
viraemia might be necessary before control is achieved42 
(eg, in one study,43 33% of rhesus macaques achieved 
durable virological control after a year following ART 
interruption). Resuming ART at the time of rebound or 
setting restart criteria too stringently might prevent 
potential complications of an ATI, but will also reduce 
the capacity to test the effectiveness of many interventions 
that aim to work through an immunological mechanisms 
and, consequently, might prevent the identification of 
viro logical controllers.44 Although a substantial reduction 
of the setpoint value following ATI compared with the 
natural pre-ART values (when available) might be 
scientifically i nteresting, i t i s g enerally a ssumed t hat 
virus control, which is comparable to that during ART, 
will be needed for regulatory approval of any intervention 
aiming to induce viral suppression in the absence of 
ART. Overall, the consensus was that no universal values 
for duration or peak of viraemia should be used as restart 
criteria but that, when setting limits, duration of viraemia 
might be more important than the amount of viraemia.
Possible viral load-based restart criteria were also 
discussed. There was some support for 12–16 weeks of 
uncontrolled viraemia as an acceptable limit in studies 
for which a stable viral setpoint is a primary endpoint. 
Another proposed limit was to tolerate a viral load of 
1000 copies per mL or more for 4 weeks (appendix p 8). 
Data from the RV217 study31 and from the FRESH 
(Females Rising through Education, Support, and 
Health) cohort45 in South Africa suggest that a viral steady 
 
state might be achieved as early as 4–6 weeks following 
acute infection, and new viral setpoints were achieved 
after 8–12 weeks following ART interruption in previous 
ATI studies.46,47 Early set point information might, 
therefore, be available if viraemia is tolerated for 
4–8 weeks. However, this approach might miss a certain 
percentage of virological controllers who would have 
achieved control at a later date. It was also suggested that 
viraemia can be tolerated for as long as viral load concen-
trations are declining naturally without a predetermined 
time limit. There was a general consensus that anyone 
who reaches confirmed HIV RNA of more than 
100 000 copies per mL in time-to-rebound studies should 
restart ART immediately, regardless of duration. If the 
endpoint, however, is viral setpoint, high viral peaks, 
even of more than 100 000 copies per mL, might need to 
be tolerated for several weeks. Overall, there was a 
consensus that each viral load measurement should be 
confirmed with a second test, and that no action should 
be taken based on a single viral load result.
There was consensus that any clinical presentation 
suggestive of being HIV-related would be an adequate 
criterion for restarting ART. Symptoms might include, but 
are not limited to, unintentional weight loss (>5–10% of 
the pre-ATI body weight), otherwise unexplained persistent 
fever (>38°C), persistent night sweats, persistent diarrhoea, 
oral candidiasis, and generalised lymphadenopathy. In 
general, such symptoms would need to be considered on a 
case by case basis.
CD4 concentrations were also considered as a criterion 
for re-initiating ART. Depending on the study and the 
participants who are enrolled, the use a confirmed 
absolute CD4 concentration (eg, CD4 <350 cells per µL or 
CD4% <15%) was proposed or, alternatively, the 
percentage of decline from the starting CD4 value 
(eg, 30–50% decline). However, the clinical relevance of 
such decline in participants with high starting CD4 
counts is unclear. Similarly to viraemia, CD4 counts 
should be confirmed with a second test before taking 
action. For studies using an absolute CD4 concentration, 
there was consensus that if the entry criterion is for 
individuals with CD4 counts of more than 500 cells per 
µL, restart concentration should be of less than 350 cells 
per µL. However, it is important to note that this cutoff  
will not be applicable in all cases and will be dependent 
on the CD4 entry criteria. Investigators should focus on 
obtaining a sufficiently large difference between the entry 
value versus a CD4 measure to compel ART resumption. 
As a practical matter, ATI experience to date shows that 
ART is resumed for criteria associated with the duration 
and magnitude of viraemia in nearly all cases.
Unprotected sex was another concern discussed in the 
meeting. It was agreed that all participants should be 
counselled before, and recurrently during, the trial on how 
best to protect their sexual partners from HIV infection. 
Although expectations for transmission precautions might 
differ, in particular when the sexual partner is reliably on 
pre-exposure prophylaxis, the group agreed that partici-
pants who engage in risky sexual behaviour, as documented 
by history or by the diagnosis of recurrent, multiple, or 
new sexually transmitted infections suggestive of unpro-
tected vaginal or anal intercourse, should be excluded from 
ATI trials or restarted on ART. Some studies are now 
including routine monitoring for sexually transmitted 
infections before and during the ATI to confirm 
participant’s adherence to barrier protection for prevention 
of HIV transmission during the treatment interruption. A 
related, but less well defined, concern is superinfection in 
a study participant during ATI, which could be a major 
bias for the study endpoints but also might pose difficulties 
for ART reinitiation.
Controlled data on ART pause and viral rebound in 
paediatric populations are scarce. Whereas for older 
children (eg, adolescents), similar restart criteria to that 
for adults might be reasonable, younger children differ 
substantially from adults (eg, in natural CD4 T-cell 
frequencies). Some investigators suggested that tolerating 
longer and higher viraemia in paediatric participants than 
adults might be considered. Overall, the group agreed 
that defining ART restart criteria would require specific 
discussions geared towards paediatric populations, which 
was outside of the scope of this meeting.
Should we avoid cure terminology?
There was consensus that cure should not be used in 
titles and the informed consent processes. Most ATI 
studies are early stage trials and are not designed to lead 
to a potential cure. Thus, the use of cure is misleading.48 
Although the group agreed that cure might be an 
appropriate term in some cases (eg, when raising public 
awareness or in a political context), there was a clear 
consensus that cure is not appropriate when applied 
to specific studies or trials and informed consent 
documents. Some group members considered that 
remission is not an acceptable substitute for cure because 
it carries negative connotations from the oncology field. 
Several alternatives were suggested, such as drug-free 
long-term control, undetectable off treatment, viral 
suppression off treatment, drug-free viral control, and 
durable viral load suppression. These terms should be 
considered for community review.
When is there sufficient justification for the ethical use 
of placebo-controlled study designs?
The use of a placebo-controlled group raises both 
scientific and ethical questions. The overall consensus 
was that the decision whether to use a placebo control 
should be driven primarily by the science, that is whether 
a placebo group is needed for the scientific validity of a 
study. If a placebo group is necessary for the findings of a 
study to be properly interpreted, it could be considered 
unethical not to include a placebo (ie, when a placebo is a 
scientific necessity, it is arguably an ethical imperative as 
well). In these scenarios, power calculations to determine 
sample size requirements for placebo and intervention 
groups should be an important consideration when 
formal statistical comparisons are planned. However, 
there was also agreement that, in early exploratory trials, 
placebo control groups are sometimes used more for 
descriptive understanding of the population studied and 
their underlying response rather than providing 
statistical power for formal hypothesis testing. Such 
studies might be able to forego placebo groups and, 
instead, use well defined historical controls for time to 
HIV rebound, with the caveat that such earlier cohorts 
might differ from current cohorts in terms of ART 
regimens or timing of ART initiation, and might, 
therefore, underestimate time to rebound compared with 
those diagnosed and starting ART in more recent years. 
It was also noted that people living with well controlled 
HIV might be reluctant to participate in trials in which 
they could be placed in a placebo group when undergoing 
ATI, if their main interest was to be exposed to an 
experimental drug; in such cases, placebo groups might 
make study enrolment less appealing.
How do we ensure informed consent and avoid 
unreasonable expectations?
Achieving and ensuring informed consent can be very 
challenging, and the individual engagement of the 
research team member(s) and the potential participant is 
essential for supporting informed consent in early phase 
clinical trials. There was consensus that trial investigators 
need to ensure that participants understand the risks 
involved with ATI studies. In addition to potential 
physical risks, informed consent documents should 
address potential social, financial, and psychological 
risks. This process also includes informing the 
participant about potential stress or worry associated 
with re-experiencing detectable viraemia or fear of 
transmitting HIV. There was some support for testing 
the participants’ knowledge of the study after informed 
consent to ensure that potential participants understand 
the procedures and risks involved in trial participation. 
Evidence from a study in Thailand36 suggests that close 
relationships between clinical trial teams and participants 
has facilitated an improved understanding of the study 
and required procedures. As a result of these close 
relationships, most participants reported feeling that 
they had made an active and informed choice to 
participate at the conclusion of the study. An important 
distinction was noted between participants who are 
misinformed (eg, those who do not understand the 
intent of the research) versus participants who display 
therapeutic optimism (eg, those who understand the 
intent of the research but are unrealistically optimistic 
about obtaining the best outcome).
Conclusion
In summary, ATIs are not yet irreplaceable for assessing 
the efficacy of interventions aimed at inducing HIV 
suppression in the absence of ART. Guidance on how 
to operationalise ATI studies to maximise scientific 
return but minimise participant’s risk is crucial. The 
recommendations and consensus viewpoints sum-
marised in this Review are thought to be a step forward 
in building consensus about how best to implement 
ATIs, taking scientific, clinical, and ethical aspects, and 
expectations into consideration. With the field rapidly 
evolving and with new data emerging, the establishment 
of an eclectic advisory group, such as the one described 
in this Review, that can regularly revisit and recommend 
changes in the approach to ATIs in HIV research studies 
should accelerate the evaluation of strategies that seek 
ART-free viral control while minimising risk to research 
participants.
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